---
schema_version: "secwatch.filing_event.v1"
accession: "0001935979-25-000067"
form_type: "8-K"
ticker: "BHVN"
cik: "0001935979"
company_name: "Biohaven Ltd."
filed_at: "2025-08-11T23:59:59+00:00"
generated_at: "2026-05-17T15:47:38.184618+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Biohaven reports Q2 net loss $198M, cash $408.2M; OCD trial fails, VYGLXIA PDUFA in Q4 2025

## Summary
- Net loss of $198.1M ($1.94 per share) vs $319.8M in Q2 2024; no revenue, clinical-stage biopharma.
- Cash, equivalents and marketable securities $408.2M as of June 30, 2025.
- Phase 3 OCD trial with troriluzole showed no efficacy signal; program terminated.
- VYGLXIA NDA for spinocerebellar ataxia under priority review, PDUFA in Q4 2025.
- Early clinical data: BHV-1300 IgG reductions up to 87%, BHV-1510 ADC showed tumor reduction in first 6/6 patients with cemiplimab.

## SEC filing metadata
- accession: 0001935979-25-000067
- form_type: 8-K
- ticker: BHVN
- cik: 0001935979
- company_name: Biohaven Ltd.
- filed_at: 2025-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1935979/000193597925000067/0001935979-25-000067-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1935979/000193597925000067/bhvn-20250811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001935979-25-000067
- JSON: https://secwatch.observer/filing/0001935979-25-000067.json
- Plain text: https://secwatch.observer/filing/0001935979-25-000067.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.